Study S001418

A Study Investigating the Pharmacokinetic Properties When Dosing Different Formulations of Semaglutide to Healthy Male Participants

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06642584
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 90
Start: 2024-10-15
Primary completion: 2025-07-10
Lead sponsor: Novo Nordisk A/S
Conditions: Healthy Volunteers Type 2 Diabetes
Interventions: DRUG:Semaglutide B; DRUG:Semaglutide J; DRUG:Semaglutide L; DRUG:Semaglutide M; DRUG:Semaglutide N
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1304-9627

Registered primary outcomes

Adjusted AUC(sema); adjusted area under the semaglutide plasma concentration-time curve [From 0 to 24 hours after dosing on Days 122 and 132.]
Adjusted Cmax,(sema); adjusted maximum observed semaglutide plasma concentration [From 0 to 24 hours after dosing on Days 122 and 132.]
Adjusted tmax,sema; time to adjusted maximum observed semaglutide plasma concentration [From 0 to 24 hours after dosing on Days 122 and 132.]
t½,sema; the terminal half-life of semaglutide [From 0 to 840 hours after dosing on Day 132.]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.